Heterogeneity in the carbohydrate structure of rat angiotensinogen

Role of N-glycosylation in human angiotensinogen

Human angiotensinogen, the specific substrate of renin, is a heterogeneous glycoprotein constitutively secreted by the liver. Different glycosylation levels may be responsible for its heterogeneity. It contains four putative asparagine-linked glycosylation sites (Asn-X-Ser/Thr). Systematic site-directed mutagenesis (Asn replaced with Gln) of these four sites was undertaken, and 11 (single, double, triple, and quadruple (N-4)) mutants were produced in COS-7 and/or CHO-K1 cells and characterized. All of the sites were N-glycosylated with preferential glycosylation of the Asn14 and the Asn271. The suppression of the Asn14 glycosylation site led to 5 times lower Km and a 10 times lower kcat. Angiotensinogen heterogeneity was much lower for the N-4 mutant protein, which produced a single form at 48 kDa. Pulse-chase experiments showed slight intracellular retention (15%) of the deglycosylated protein after 24 h. Interestingly, the N-4 mutant had a higher catalytic efficiency (kcat/Km = 5.0 versus 1.6 microM-1 . s-1) than the wild-type protein. The thermal stability of the N-4 protein was unaffected by deglycosylation, suggesting that it was correctly folded. This deglycosylated recombinant human angiotensinogen could be of value for x-ray crystallography studies.

Molecular forms of rat angiotensinogen in plasma and brain: identification by isoelectric focusing and immunoblot analysis

Angiotensinogen (Ao) is the glycoprotein precursor of the vasoactive peptide angiotensin II. While Ao is synthesized as multiple molecular forms, the biochemical characteristics of this protein in blood and other tissues have not been defined. In this study, the charge heterogeneity of Ao in rat plasma, cerebrospinal fluid and that secreted by astrocyte and neuronal cultures was examined using analytical isoelectric focusing in combination with immunoblotting and quantitative image analysis. Normal rat male plasma Ao separated into 9 isoforms in the pI range 4.34-4.92 (1, 4.34; 2, 4.41; 3, 4.48; 4, 4.58; 5, 4.61; 6, 4.66; 7, 4.68; 8, 4.81; 9, 4.92); the percentage contribution of each to total plasma Ao was 13, 20, 23, 18, 2, 7, 10, 5, and < 1, respectively. A similar isoelectric focusing pattern was observed in female rat plasma with the exception that the relative contribution of isoform 6 was reduced to 2% of total Ao. Cerebrospinal fluid Ao displayed a more diverse charge heterogeneity than plasma Ao, focusing over a broader pI range of 4.42-5.24. Astrocytes and neurons secreted Ao isoforms in the pI range 4.44-5.29 and 4.42-4.95, respectively, with the astrocyte cultures showing additional bands towards the cathode. It was concluded that rat Ao is secreted as multiple charged forms that are regulated in a sex- and cell-specific manner. These differences between plasma and brain Ao suggest a functional diversity, a view which is supported by recent evidence linking Ao variants to hypertension.

Location and secretion of brain angiotensinogen

Angiotensinogen is a glycoprotein with intriguing structural similarities to the serine proteinase inhibitors but with only one known function: to act as a substrate in the enzymatic generation of angiotensin peptides. It is expressed as a constitutive protein by the liver and various other tissues, including the brain. It is in this tissue that the expression of angiotensinogen attains its most complex and controversial manifestations. In late gestation, an unfolding of cellular expression occurs, starting at an epicentre in the eppendymal and astroglia cells of the hypothalamus, which rapidly and sequentially spreads to sub-cortical and then cortical regions, concentrating at sites of electrolyte, fluid and pressure regulation. This initial burgeoning of astroglial angiotensinogen is trailed by a wave of neuronal expression in various limbic and sensorimotor regions of the brain. The predominance of AT2 receptors in these regions suggests that the RAS actions are mediated by AT2 receptors. The angiotensinogen found in the CSF and secreted by cultures of glia and neurones is similar to the two major molecular sizes found in plasma. However, by electrophoretic separation on the basis of charge imparted by differential glycosylation, it can be shown that glia and neurones secrete distinct forms. The expression of different forms is under hormonal regulation. If these structural forms are shown to affect function, then the resulting ramifications may extend to pathological conditions, such as hypertension. Primary cell cultures of astrocytes secrete angiotensinogen constitutively and in a region-specific manner related to the size of the sub-population of secretory cells. Neurone cultures secrete angiotensinogen at about 25% the rate of hypothalamic astrocytes. The use of RT-PCR shows that both cell types express angiotensinogen mRNA. There is still an unresolved mismatch between these data and in situ hybridization histochemistry which shows expression limited to astrocytes but it is suggested that changes to more appropriate techniques will resolve any outstanding discrepancies.

Leukocytes synthesize angiotensinogen

To determine whether leukocytes express the angiotensinogen gene, we subjected circulating rat leukocytes and murine bone marrow cells to Northern blot analysis and hybridization with homologous angiotensinogen complementary DNA. Angiotensinogen messenger RNA sequences were detected in circulating adult rat leukocytes, in murine-irradiated and nonirradiated bone marrow stromal cells, and in an adherent stromal cell line (preadipocyte). Western blot analysis of rat leukocyte homogenate showed that rat leukocytes contain two main angiotensinogen isoforms with approximate molecular weights of 46.5 and 53.9 kd. Synthesis and release of angiotensinogen protein by rat leukocytes was confirmed by immunoprecipitation of radiolabeled angiotensinogen from cell lysate and media of rat leukocytes that were metabolically labeled with 35S-L-methionine. In addition, the angiotensinogen protein present in media of rat leukocytes was enzymatically cleaved by hog renin, resulting in generation of angiotensin I (305 +/- 47 pg angiotensin I per milliliter of media per hour). We conclude that circulating rat leukocytes express the angiotensinogen gene and synthesize and release angiotensinogen with the capability to generate angiotensin. Expression of angiotensinogen by leukocytes may provide a mobile angiotensin-generating system of potential importance in the regulation of local inflammatory responses, tissue injury (i.e., myocardial infarction), and arterial hypertension.

Angiotensinogen is secreted by pure rat neuronal cell cultures

Previous studies are divided between those which support a neuroglial (astrocyte) source for brain angiotensinogen and those which indicate that both astrocytes and neurones synthesize the precursor of angiotensin II. In this study, separate cultures of astrocytes and neuronal cells were prepared and established as being essentially pure by appropriate immunocytochemical cell markers. Angiotensinogen production by these cultures, as measured by a direct radioimmunoassay, was 20.74 +/- 3.62 ng angiotensinogen/10(6) cells/24 h (mean +/- S.D., n = 8) for astrocytes and 4.39 +/- 0.94 ng/10(6) cells/24 h (mean +/- S.D., n = 29) for neurones. Angiotensinogen secretion from both cell types was unaffected by treatments which stimulate the regulatory secretory pathway by modulating intracellular cAMP levels. In contrast, it was reduced from 23.20 +/- 2.14 to 8.14 +/- 1.31 ng/10(6) cells/24 h (S.E.M., n = 7) in astrocyte cultures by the constitutive pathway inhibitor, monensin. Angiotensinogen secreted by astrocytes and neurones was compared to pure angiotensinogen and that in plasma and cerebrospinal fluid (CSF) by cation-exchange mono S column chromatography. Pure angiotensinogen eluted as two separate peaks corresponding to the major forms of plasma angiotensinogen, whereas angiotensinogen in CSF and culture media coeluted with a third minor form of plasma angiotensinogen. It was concluded that neuronal cells as well as astrocytes secrete angiotensinogen which is distinctly different from plasma angiotensinogen.

Immunccytochemical localization of angiotensinogen in rat brain: dependence of neuronal immunoreactivity on method of tissue processing

Abstract There is disagreement between laboratories on the presence and location of angiotensinogen immunostaining in neuronal cells. We examined this issue by using different antisera and histological procedures to stain for angiotensinogen in brains from normal, colchicine-treated and nephrectomized rats. Five different antisera from three laboratories were used to stain sections of paraffin-embedded tissue, frozen sections and Vibratome sections of cerebral cortex, thalamus, hypothalamus, brainstem and cerebellum. All five antisera and all three tissue treatments were effective in showing angiotensinogen staining in glial cells, with the most intense staining being achieved in Vibratome sections. All five antisera gave identical results. Neuronal staining was also found with all antisera but mostly in paraffin-embedded sections, with occasional light staining in frozen sections. No neuronal staining was observed in Vibratome sections. Neuronal staining was frequently perivascular, tended to have a more variable anatomical localization, and to occasionally lack bilateral symmetry in coronal sections. These results provide an explanation for the disagreement between laboratories on the presence and location of angiotensinogen immunostaining in neuronal cells. Taken together with the limited concordance between published sites of angiotensinogen and angiotensin II staining, and the recent demonstration by hybridization in situ of a specifically glial cell localization of angiotensinogen mRNA, our own results suggest a need for caution in the interpretation of neuronal staining with anti-angiotensinogen antisera.

Half-life of rat angiotensinogen: influence of nephrectomy and lipopolysaccharide stimulation

The in vivo half-life of two differently glycosylated subforms of rat angiotensinogen (Ao), Ao-1 and Ao-2, was studied in native and nephrectomized rats, as well as in rats treated with lipopolysaccharides (LPS). The metabolic clearance rate of both 125I-labeled derivatives fits a two-compartment model using a non-linear curve fitting program (SCTFIT). Both forms show an initial rapid phase with a half-life of about 1 h. This clearance rate was not altered by either nephrectomy or LPS administration. In the intact rat the two forms were eliminated with a second slower phase half-life of 8.07 h (Ao-1) and 4.53 h (Ao-2), respectively. Following nephrectomy, in the absence of renin, the slower phase of clearance of both forms decreased (t1/2 Ao-1:9.77 h; t1/2 Ao-2: 10.50 h). Induction of low renin concentrations by LPS administration decreased the half-life of the more highly glycosylated form Ao-1 (t1/2: 6.93 h), while that of Ao-2 increased (t1/2: 5.07 h). Inactive angiotensinogen, des-AngI-Ao, of both forms demonstrated a faster metabolic clearance rate in native rats than that of the intact glycoproteins (t1/2 Ao-1: 5.68 h; t1/2 Ao-2: 3.97 h). Based on the plasma levels of these two angiotensinogen subtypes in normal rats, these data suggest a higher secretion rate by the liver for the more highly glycosylated form Ao-1 and a slower clearance rate by the kidney. In contrast, the less glycosylated form shows more rapid elimination by the kidney. Following nephrectomy both glycoproteins are secreted and eliminated in an equimolar ratio.(ABSTRACT TRUNCATED AT 250 WORDS)